On March 17, 2023 Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, reported that data from the company’s leading program fostroxacitabine bralpamide (fostrox) and its potential effect on hepatocellular carcinoma (HCC), will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, on April 14-19, in Orlando, USA (Press release, Medivir, MAR 17, 2023, View Source [SID1234628999]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The abstract, titled "A triple combination of fostrox (MIV-818) with immune checkpoint and kinase inhibition shows increased anti-tumor efficacy in vivo" will be presented at the conference by Fredrik Öberg, CSO at Medivir. The presentation includes study results describing the potential for enhanced anti-tumor effects when fostrox is combined with both an anti-PD1 antibody and a kinase inhibitor.
– "Inhibition of angiogenesis has the potential to increase the effect of fostrox and the induction of DNA damage and tumor cell death. This can lead to increased tumor antigen presentation and a strengthened immune response, which creates opportunities to combine with both checkpoint inhibitors and tyrosine kinase inhibitors. In line with this, our preclinical results show that fostrox has the potential to amplify anti-tumor activity together with a combination of anti-PD-1 antibodies and kinase inhibitors", says Fredrik Öberg.
– "Although existing combination therapies for HCC can prolong patients’ lives, far from all patients respond to treatment. In order for more patients to have a satisfactory treatment effect, new combination options with several different, additive mechanisms of action will be crucial. Fostrox, with its unique, liver-directed approach, opens up for completely new combinations with three different approaches to effectively treat HCC.", says Pia Baumann, CMO at Medivir.
The abstract and the poster will be available on Medivir’s website after the presentation.
For additional information, please contact
Magnus Christensen, CFO, Medivir AB
Telephone: +46 8 5468 3100
E-mail: [email protected]
About fostrox
Fostroxis a pro-drug designed to selectively treat liver cancers and to minimize side effects. It has the potential to become the first liver-targeted and orally administered drug for patients with HCC and other forms of liver cancer. Fostrox has completed a phase 1b monotherapy study, and a combination study in HCC currently ongoing.
About primary liver cancer
Primary liver cancer is the third leading cause of cancer-related deaths worldwide and hepatocellular carcinoma (HCC) is the most common cancer that arises in the liver. Although existing therapies for advanced HCC can extend the lives of patients, treatment benefits are insufficient and death rates remain high. There are 42,000 patients diagnosed with primary liver cancer per year in the US and current five-year survival is 11 percent. HCC is a heterogeneous disease with diverse etiologies, and lacks defining mutations observed in many other cancers. This has contributed to the lack of success of molecularly targeted agents in HCC. The limited overall benefit, taken together with the poor overall prognosis for patients with intermediate and advanced HCC, results in a large unmet medical need.